. 2019 Jun 1;8(11):e012584. doi: 10.1161/JAHA.119.012584

Table 2.

Urinary EV Representing Different Nephron Segments in Hypertensive Patients and HVs

EV Parameter	HV	EH	RVH
Count, TIV⁺	25 389 (10 573–41 903)	23 689 (11 656–32 585)	17 639 (11 317–34 723)
%, TIV⁺	50.8 (21.4–83.8)	47.4 (23.3–65.2)	35.3 (22.6–69.5)
%, p16⁺	18.6±7.7	27.9±8.4^a	24.6±6.5^a
Podocalyxin
%, Podxl⁺p16⁺	0.035 (0.01–0.07)	0.046 (0.01–0.13)	0.039 (0.01–0.11)
%, Podxl⁺p16⁺MCP1⁺	0.41 (0.03–1.49)	0.57 (0.02–2.15)	0.51 (0.03–1.74)
URAT1
%, URAT1⁺p16⁺	7.6±5.2	31.3±20.6^a	40.2±17.6^a
%, URAT1⁺p16⁺MCP1⁺	15.4±17.3	21.7±22.7^a	28.9±14.6^a
Uromodulin
%, Umod⁺p16⁺	7.7 (0.9–16.2)	15.1 (1.3–36.6)	36.5 (20.3–43.9)^a, ^b
%, Umod⁺p16⁺MCP1⁺	2.3 (0.12–10.87)	6.6 (0.73–22.40)	9.3 (0.56–28.40)^a
Prominin2
%, Prom2⁺p16⁺	2.32 (0.32–7.80)	5.9 (1.1–22.7)^a	3.5 (0.8–7.6)
%, Prom2⁺p16⁺MCP1⁺	3.0 (0.5–9.3)	4.6 (1.5–11.4)	5.6 (1.3–10.6)^a

EH indicates essential hypertension; HVs, healthy volunteers; MCP, monocyte chemoattractant protein; Podxl, podocalyxin; Prom2, prominin‐2; RVH, renovascular hypertension; TIV, tag‐it‐violet; Umod, uromodulin; URAT‐1, urate transporter 1.

P<0.05 vs HV.

P<0.05 vs EH.